Idexx Laboratories (IDXX)
NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$555.67-2.56%
Close 2026-07-08 · 1-day change
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on growth in recurring revenue. The current thesis state is intact, supported by strong recent financial performance, though management execution has been mixed.
The market appears to be pricing in a durable premium, reflecting expectations for continued growth. However, the valuation is considered expensive compared to peers, indicating that some positive outcomes are already anticipated.
Fundamentals are likely to show continued strength in recurring revenue, particularly in CAG Diagnostics, which has seen solid growth. However, the mixed execution from management raises some concerns about achieving the higher revenue and EPS guidance.
The long-term thesis hinges on the performance of sector bellwethers like TMO, DHR, and NTRA. If these companies continue to perform well, it could provide a favorable backdrop for IDXX, while any negative guidance from them could pose risks.
In the next 1 to 3 years, IDXX's performance will depend on sector dynamics and management's ability to deliver on guidance. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation rose by 10.6 points (from 39.1 to 49.7).
Mixed, the news cuts both ways. The latest earnings beat supports the read, indicating strong financial performance. However, a recent article suggests that IDEXX Laboratories needs more tests per vet visit to expand its recurring revenue, which poses a challenge to growth.
as of 2026-07-08
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show if the company meets growth expectations. It can shift investor views.
Confirms one read:Q2 earnings beat analyst expectations. Revenue grew by more than 10%.
Confirms the other:Q2 earnings miss expectations with revenue growth below 5%.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Continued strong growth in CAG Diagnostics is key to IDEXX's overall performance. It shows if the company can maintain momentum.
Confirms:CAG Diagnostics recurring revenue growth exceeds 14% year over year in Q2.
Disproves:CAG Diagnostics recurring revenue growth falls below 11% year over year in Q2.
Why it matters: Changes in leadership can change company strategy and performance. Watch this to see future plans.
Confirms one read:Good performance numbers came in after Michael Erickson became CEO.
Confirms the other:Bad performance numbers came in after Michael Erickson became CEO.
Why it matters: Changes in EPS guidance show that management is sure about making money. This shows business health.
Confirms one read:EPS guidance for 2026 is raised above $14.90.
Confirms the other:EPS guidance for 2026 is lowered below $14.45.
Why it matters: EPS growth shows how much money the company makes. Confirmation backs up management's plans.
Confirms:2026 EPS lands within the range of $14.45 - $14.90 in Q2 2026.
Disproves:2026 EPS falls below $14.29 in Q2 2026.
Why it matters: If revenue guidance goes up, it shows IDEXX is confident in its growth.
Confirms:Management raises 2026 revenue guidance to more than $4,760 million.
Disproves:Management keeps or lowers 2026 revenue guidance to less than $4,675 million.
Why it matters: The new CEO's style may change how the company performs. This change could affect investor trust.
Confirms one read:Watch for good market reactions or better numbers after Michael Erickson becomes CEO on May 12, 2026.
Confirms the other:Bad market reactions or worse operational numbers after the CEO change.
Why it matters: A higher EPS outlook shows better profit expectations. This can help stock sentiment.
Confirms:Management increased the EPS outlook for 2026. It is now higher than current estimates.
Disproves:Management keeps or lowers the EPS outlook for 2026.
Why it matters: The success of the inVue Dx rollout is critical for future growth and innovation in diagnostics.
Confirms:Customers gave good feedback. They also showed high adoption rates after the rollout.
Disproves:Customers gave bad feedback. They showed low adoption rates after the rollout.